AMAG Pharmaceuticals repays, terminates term loan via convertibles

By Tali Rackner

Minneapolis, May 15 – AMAG Pharmaceuticals, Inc. repaid about $321.8 million of outstanding borrowings and accrued interest under its $350 million term loan facility and terminated the facility on Thursday, according to an 8-K filing with the Securities and Exchange Commission.

The company used the proceeds from a new convertible senior note offering and cash on hand.

On Wednesday, the company completed its offering of $300 million 3.25% convertible senior notes due 2022. Net proceeds totaled about $291 million.

AMAG is a Waltham, Mass.-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.